Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  2. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.

    Article  CAS  Google Scholar 

  3. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a ten-year follow-up. Leukemia 1998; 12: 887–892.

    Article  CAS  Google Scholar 

  4. Hugues L, Cave H, Philippe N, Pereira S, Fenaux P, Preudhomme C . Mutations of PTPN11 are rare in adult myeloid malignancies. Haematologica 2005; 90: 853–854.

    PubMed  Google Scholar 

  5. Johan MF, Bowen DT, Frew ME, Goodeve AC, Wilson GA, Peake IR et al. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2004; 124: 843–844.

    Article  CAS  Google Scholar 

  6. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F Activating Tyrosine Kinase Mutation is an Infrequent Event in Both ‘Atypical’ Myeloproliferative Disorders and the Myelodysplastic Syndrome. Blood 2005; 106: 1207–1209.

    Article  CAS  Google Scholar 

  7. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.

    Article  CAS  Google Scholar 

  8. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML . SHP-2 and myeloid malignancies. Curr Opin Hematol 2004; 11: 44–50.

    Article  CAS  Google Scholar 

  9. Yin T, Shen R, Feng GS, Yang YC . Molecular Characterization of Specific Interactions between SHP-2 Phosphatase and JAK Tyrosine Kinases. J Biol Chem 1997; 272: 1032–1037.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from the National Science Council of the Republic of China NSC 93-2314-B002-038 and NSC 94-2752-B002-006-PAE, National Taiwan University Hospital NTUH 93-5051 and the Department of Medical Research in National Taiwan University Hospital, Taiwan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H-F Tien.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, CY., Lin, LI., Tang, JL. et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 20, 1155–1158 (2006). https://doi.org/10.1038/sj.leu.2404190

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404190

This article is cited by

Search

Quick links